speedy/RINGO cell cycle regulator family member E22, pseudogeneGenealiases: []
Q-omics provides the consensus-scored SPDYE22P profile across patient tissues and cancer cell-line models. SPDYE22P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPDYE22P is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, SPDYE22P RNA expression shows 12,995 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where SPDYE22P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDYE22P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDYE22P survival associations across molecular data types. SPDYE22P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDYE22P RNA expression–survival associations across cancer types. High SPDYE22P expression shows unfavorable associations in KIRC, KICH, ACC, COAD, LIHC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPDYE22P RNA expression.
This table summarizes SPDYE22P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPDYE22P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDYE22P shows higher tumor expression in BLCA, COAD, LUSC, STAD, LUAD and KIRC. The BLCA box plot shows higher SPDYE22P RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .008).
This table shows molecular features associated with SPDYE22P in patient tissues and cancer cell lines. In patient samples, SPDYE22P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
